### **BIOMARIN PHARMACEUTICAL INC**

Form 4

March 05, 2015

# FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**SECURITIES** 

**OMB** Number:

3235-0287

Expires:

5 Relationship of Reporting Person(s) to

January 31, 2005

0.5

Estimated average burden hours per

**OMB APPROVAL** 

response...

if no longer subject to Section 16. Form 4 or Form 5

obligations

may continue.

See Instruction

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

2 Jaguar Nama and Tiakar or Trading

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person \*

LAPALME PIERRE			2. Issuer Name and Ticker or Trading Symbol BIOMARIN PHARMACEUTICAL				S. Relationship of Reporting Person(s) to Issuer			
			C [BMRN]				(Check all applicable)			
(Last) (First) (Middle)  C/O BIOMARIN PHARMACEUTICAL INC., 105			3. Date of Earliest Transaction (Month/Day/Year) 03/03/2015				_X Director 10% Owner Officer (give title below) Other (specify below)			
DIGITAL I		,								
	(Street)		Filed(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
NOVATO,	CA 94949					1	Form filed by M Person	ore than One Re	porting	
(City)	(State)	(Zip)	Table I - Non-I	Derivative	Secur	ities Acqu	ired, Disposed of	, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Datany (Month/Day/Y	Code Year) (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)  (A) or		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Common Stock	03/03/2015	03/03/2015	Code V M	Amount 10,000	(D)	Price \$ 11.15	40,150	D		
Common Stock	03/03/2015	03/03/2015	M	10,000	A	\$ 17.33	50,150	D		
Common Stock	03/03/2015	03/03/2015	S	20,000	D	\$ 106.57 (1)	30,150	D		
Common Stock							1,500	I	Shares held by	

spouse

(9-02)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amour or Numbe of Shar
Stock Option (right to buy Common Stock)	\$ 11.15	03/03/2015	03/03/2015	M	10,000	07/27/2006(2)	01/26/2016	Common Stock	10,00
Stock Option (right to buy Common Stock)	\$ 17.33	03/03/2015	03/03/2015	M	10,000	12/07/2007(4)	06/06/2017	Common Stock	10,00

# **Reporting Owners**

Reporting Owner Name / Address	Relationships				
coposing of the rame, reaction	Director	10% Owner	Officer	Other	
LAPALME PIERRE C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO, CA 94949	X				
Signatures					

/s/ Laura Randall Woodhead, 03/05/2015 Attorney-in-Fact

Reporting Owners 2

## Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

\*\*Signature of Reporting Person

Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The price in column 4 is an average weighted price. The price actually received ranged from \$106.20 to 106.895. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the amount of shares sold at each price within the range.
- (2) Original option grant vests 6/48ths on July 27, 2006, and 1/48th on the 27th of each month thereafter.
- (3) Reflects the number of stock options that remain outstanding from this specific stock option grant following the reported transaction.
- (4) Original option grant vests 6/48ths on December 7, 2007, and 1/48th on the 7th of each month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3